Ancon Medical to wear red for World Encephalitis Day, encourage early screening

Support World Encephalitis Day Wear Red!

Medical device screening maker developing less intrusive tests for encephalitis, more than 400 other diseases

By wearing red this Thursday, you can help bring more focus on the disease and its symptoms.”

— Wesley Baker – CEO of Ancon Medical

BLOOMINGTON, MN, UNITED STATES, February 21, 2018 /EINPresswire.com/ — An innovative medical device maker is joining with the worldwide medical community to wear red for World Encephalitis Day and to encourage early screening for the unpredictable disease that can affect a wide range people in different manners.

Ancon Medical Inc. CEO Wesley Baker said that wearing red clothing on Thursday, Feb. 22 will raise awareness of the rare, but dangerous, disease and encourage early screening.

Ancon Medical developed Nanoparticle Biomarker Tagging (NBT), an advanced medical screening technology behind a groundbreaking medical screening device that can find the “fingerprint” of many types of diseases through a simple breath test, including encephalitis.

“Though encephalitis is a serious disease that can have impactful consequences, surveys show that up to 80 percent of the public isn’t even aware of the disease or its effects,” Baker said. “By wearing red this Thursday, you can help bring more focus on the disease and its symptoms. Like many other diseases, early detection of encephalitis is vital, and the sooner and easier this can happen, the better the outcome for the patient.”

Encephalitis is a disease that causes the swelling of the brain. It can be caused by a number of different viruses or it can occur when the immune system attacks the brain in error.

The disease can affect individuals of all ages, each potentially in different ways. And while rarely fatal, it can have serious consequences, including memory loss, partial paralysis, nerve damage and can even send patients into a coma. Screening for encephalitis can also be a challenge for patients, as methods can include MRIs, CT scans, spinal taps and even a brain biopsy in some cases.

Ancon Medical’s NBT device offers a convenient alternative to invasive testing, especially for early screening. The device detects the tell-tale “biomarker,” a DNA-protein controlled volatile organic compounds (VOCs) metabolites specific to diseases, which is exhaled by an infected individual.

By using Nanoparticle Biomarker Tagging technology to scan for those molecules, an NBT device can detect the biomarker in trace amounts down to a single molecule, with a sensitivity of one ion in 10,000 cubic centimeters.

All that’s needed is for researchers to discover the specific biomarker molecule for each specific diseases, as they have with encephalitis and more than 400 other diseases including cervical cancer, lyme disease, lung cancer, the Ebola virus, tuberculosis and COPD. Once identified, the NBT device can be programmed to search for the target molecule.

“An NBT device offers many advantages for medical offices and clinics that provide health screenings. It is affordable, compact, versatile and can be operated by non-medical staff,” Baker said. “A medical office equipped with an NBT device can offer non-invasive screening, providing a first warning that people can use to get the critical early treatment so necessary for so many diseases, including encephalitis.”

Ancon Medical and its associated company Ancon Technologies Ltd., has patents on NBT technology in both the U.S. and U.K. Ancon Medical is a member of Medical Alley, a Medical trade association based in Minnesota.

Joanna Stephens
Ancon Technologies & Ancon Medical
+44 1227 811705
email us here


Source: EIN Presswire

Ostomy Care Market, a Global Standpoint Till 2024 : Polaris Market Research

Global Ostomy Care Market is expected to grow from USD 2.9 billion in 2017 to USD 4.1 billion by 2024, at a CAGR of 4.4% during the forecast period

BROOKLYN, NY, UNITED STATES, February 20, 2018 /EINPresswire.com/ — According to a study published by Polaris Market Research, global ostomy care market indicates that the market generated USD 2.9 billion in 2017and is anticipated to grow at a CAGR of 4.4% during the forecast period.

An ostomy, also known as stoma is a surgical procedure that involves the removal of diseased portions of the urinary or gastrointestinal system and formation of an artificial opening in the stomach or abdomen to allow the elimination of body wastes. Moreover, the indication necessitating ostomy care includes colorectal cancer, Crohn’s disease, Bladder cancer, birth defects, ulcerative colitis, and other intestinal or urinary medical conditions. Around 140,000 people in the United States undergo operations that result in a colostomy or ileostomy every year. Additionally, according to industry sources, colorectal cancer accounts for 45% of surgeries and bladder cancer for 10%. Diverticultis and inflammatory bowel disease (IBD) account for 15% and 10%, respectively.

The global ostomy care market is driving due to the rising geriatric population and increase in the number of patients requiring ostomy surgeries with the high incidence rate of bladder/bowel cancer, Crohn’s disease, and ulcerative colitis. Moreover, technological advancements and rising number of awareness programs to educate patients for the use of ostomy products are the key factors responsible for the growth of the market over forecast period.

Polaris Market Research provides an extensive qualitative and quantitative analysis of the market trends and growth prospects of the global ostomy care market, 2017-2024. This report comprises a detailed geographic distribution of the market across North America, Europe, APAC and South America, and MEA. North America is further segmented into U.S., Canada, and Mexico. Europe is divided into Germany, UK, Italy, France, and Rest of Europe. Asia-Pacific is bifurcated into China, India, Japan, and Rest of Asia-Pacific. In 2017, Europe dominates the ostomy care market and accounted for 55% of the market.

Key Segmentation

As per the analysts of Polaris Market Research, the market segmentation is as below:
Segment – 1. By Product

1.1 Bag
1.1.1 Surgery Type
1.1.1.1 Colostomy
1.1.1.2 Ileostomy
1.1.1.3 Urostomy

1.1.2 System
1.1.2.1 One- Piece System
1.1.2.2 Two-Piece System

1.1.3 Shape
1.1.3.1 Flat
1.1.3.2 Convex

1.1.4 Usability
1.1.4.1 Closed
1.1.4.2 Drainable

1.2 Accessories
1.2.1 Creams
1.2.2 Deodorants
1.2.3 Powders & Pastes
1.2.4 Cleansers, Belt, Tapes
1.2.5 Others

Segment – 2. By End User

2.1 Hospitals
2.2 Specialty Clinics
2.3 Home Care Settings
2.4 Ambulatory Surgical Centers

Segment – 3. Region
3.1 North America
3.1.1 U.S.
3.1.2 Canada
3.1.3 Mexico

3.2 Europe
3.2.1 Germany
3.2.2 UK
3.2.3 France
3.2.4 Italy
3.2.5 Rest of Europe

3.3 Asia-Pacific
3.3.1 China
3.3.2 India
3.3.3 Japan
3.3.4 Rest of Asia-Pacific

3.4 Latin America
3.4.1 Brazil
3.4.2 Rest of Latin America

3.5 Middle East and Africa

Competitive Landscape and Key Vendors

The Global Ostomy Care Market is characterized by the presence of well-diversified global and local vendors. These companies are consistently launching new products to enhance their offerings in the market. With the advancement of technologies and the product inventions, companies are innovating and introducing new customized products to cater the growing needs of the customers.

Leading Companies investigated in the Report are

• Coloplast
• ConvaTec Inc.
• Hollister Incorporated
• Alcare Co., Ltd.
• B. Braun Melsungen AG
• BAO-Health
• Welland Medical Limited
• Marlen International
• Nu-Hope Laboratories, Inc.
• Flexicare Medical Limited

Key players such as Coloplast, ConvaTec Inc., and Hollister Incorporated are the highest market sharing companies with a combined share of 90%. Coloplast’s SensuraMio and its SpeediCathrange intermittent catheters and Hollister incorporated manufactured New Image ostomy bag and VaproPlus intermittent catheter are highly featured products which are enhancing the company’s global portfolio. Hollister is at pole position in the U.S. with about a 50% market share and is also active in the Asia Pacific. Convatec, a former subsidiary of Bristol-Myers till 2008 is now held by the private equity firms Nordic Capital and Avista Capital with approximately 30% global share. Convatec is more globally present than Hollister, with a robust position in Europe, leading position in Latin America, and a smaller position in Asia.

Browse other reports by Polaris Market Research:

https://www.polarismarketresearch.com

Neel
Polaris Market Research & Consulting
+16465689980
email us here


Source: EIN Presswire

Aviv Biomedical Announces Launch of New Website for their AVIV-BHS Bilirubin Hematofluorometer

Aviv Biomedical

WWW.AVIVBHS.COM

LAKEWOOD, NEW JERSEY, USA, February 20, 2018 /EINPresswire.com/ — Lakewood, New Jersey, 14 January 2018 – Aviv Biomedical proudly announces the launch of its new website at www.avivbhs.com showcasing the AVIV-BHS Bilirubin Hematofluorometer System, for assessment of jaundice in newborn babies. The new website explains the principles of operation for Aviv’s latest instrument which is currently in clinical trials at a leading US hospital.

The AVIV-BHS instrument allows, for the first time, the rapid measurement in neonates of Bilirubin Binding Capacity (BBC), a critical factor in preventing or allowing the development of neonatal jaundice. Bilirubin is neurotoxic, and high levels following birth can result in grave illnesses including seizures, cerebral palsy and kernicterus.

Aviv is working with The Sage Group to identify a partner with whom it will roll out its ground-breaking AVIV-BHS globally.

Florence Aviv, Aviv’s President, stated, “We are delighted to announce the launch of our new website, www.avivbhs.com, for this ground-breaking new instrument from Aviv, allowing assessment of risk of neonatal jaundice with high accuracy. This capability should transform neonatal treatment with huge economic benefits for healthcare systems worldwide. Our main priority now is to identify one or more global partners with whom Aviv can work to roll out the AVIV-BHS as widely as possible.”

About Aviv Biomedical
Aviv Biomedical (“Aviv”) is a leading edge medical instrumentation developer. It was founded in 1971 by the late Jack Aviv in Lakewood NJ USA, initially to service spectrophotometers, circular dichroism spectrometers and spectrofluorometers. The company is a family-owned enterprise run today by the Aviv family.

Since 1971, Aviv Biomedical has strived to provide the best scientific instruments and support possible. The product line includes a ZPP hematofluorometer for whole blood screening for iron deficiency and lead poisoning. Aviv strives to produce an unparalleled medical instrument capability and provide superior service.

For more information about Aviv Biomedical and partnering opportunities for the AVIV-BHS, please contact:
Dr. Bill Mason
The Sage Group
The Old Black Barns
Lord’s Lane, Ousden CB8 8TX UK
Tel: +44 (0) 7785 950134
wtm@sagehealthcare.com

Dr. Bill Mason
The Sage Group
+44 7785 950134
email us here


Source: EIN Presswire

Myositis Support and Understanding Joins Rare Disease Day 2018

Myositis Support and Understanding Association logo

Myositis Support and Understanding Association, Inc.

Dr. Victoria Werth, MD, joins MSU for online video session,Overview and new developments in dermatomyositis

Dr. Victoria Werth, MD, joins MSU for online video session, Overview and new developments in dermatomyositis

Nurse and MSU medical advisor Vicky Starr, RN, IgCN, joins MSU for IV and SubQ IG Therapy for Myositis

Nurse and MSU medical advisor Vicky Starr, RN, IgCN, joins MSU for IV and SubQ IG Therapy for Myositis

Myositis Support and Understanding Association Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases like Myositis

Myositis patients are often well-educated patients who are willing to research in order to learn more about their disease to effectively advocate for themselves and make informed medical decisions.”

— Jerry Williams

LINCOLN, DE, USA, February 20, 2018 /EINPresswire.com/ — Myositis Support and Understanding Association (MSU) has joined forces with 30 million Americans and health care advocates around the world for Rare Disease Day® on February 28. Rare Disease Day is an annual awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people face.

As part of the MSU patient-centered focus and commitment to educating and supporting those with myositis, a rare disease, MSU is hosting two live online video education sessions on Rare Disease Day, February 28, 2018, as well as a month-long celebration with patient support and activity sessions. The focus for MSU is the idiopathic inflammatory myopathies, which includes dermatomyositis, polymyositis, juvenile dermato- and poly- myositis, inclusion body myositis, and necrotizing autoimmune myopathy.

Dr. Victoria Werth, MD, will join MSU for a live, online video education session titled “Overview and new developments in dermatomyositis” at 2PM EST on Rare Disease Day.

Also, Nurse Vicky Starr, RN, IgCN, will join MSU for a live, online video education session at 6PM EST on Rare Disease Day, titled “IV and SubQ IG Therapy for Myositis.”
Register for these online video education sessions by visiting the MSU Events page at UnderstandingMyositis.org/events. Both Rare Disease Day events are open to the public and are free of charge. For assistance with these sessions, please contact Jerry Williams at info@understandingmyositis.org.

Jerry Williams, Founder and President of MSU, will also be attending Rare Disease Week on Capital Hill this year to learn more about advocacy efforts for Rare Disease patients and to discuss several topics of interest for the myositis community with lawmakers and other Rare Disease advocates.

MSU works each and every day to give Myositis patients a brighter future. Aside from the important support, advocacy, and education programs, MSU also offers a need-based financial assistance program for myositis patients for medical-related expenses and travel, as well as some household expenses.
MSU helps to match patients with clinical trials to help researchers find the often-difficult number of patients required for a rare disease clinical trial, and to help patients access these important myositis research studies.

“Rare Disease patients, in our case those living with one of the idiopathic inflammatory myopathies (myositis), are often well-educated patients because they are willing to research and reach out to others for shared experiences in order to learn more about their disease so they can effectively advocate for themselves and make informed medical decisions,” says Jerry Williams.

According to the National Institutes of Health (NIH), a disease is rare if it affects fewer than 200,000 people. Nearly 1 in 10 Americans live with a rare disease—affecting 30 million people—and nearly half of these patients are children. There are more than 7,000 rare diseases and only approximately 450 FDA- approved medical treatments. With Myositis, the estimates are approximately 50-75K patients are living with a type of myositis in the U.S.
Rare Disease Day takes place every year on the last day of February (February 28 or February 29 in a leap year)—the rarest date on the calendar—to underscore the nature of rare diseases and what patients face.

It was established in Europe in 2008 by EURORDIS, the organization representing rare disease patients in Europe, and is now observed in more than 80 nations. Rare Disease Day is sponsored in the U.S. by the National Organization for Rare Disorders (NORD)®, the largest and leading independent, nonprofit organization committed to the identification, treatment, and cure of rare diseases.

For more information about Rare Disease Day in the U.S., go to www.rarediseaseday.us. For information about global activities, go to www.rarediseaseday.org. To search for information about rare diseases, visit NORD’s website, www.rarediseases.org.

For more information about idiopathic inflammatory myopathies (myositis) visit UnderstandingMyositis.org.

###

Media contacts:
Jerry Williams, MSU, info@UnderstandingMyositis.org
Laura Mullen, NORD, 203-744-0100, media@rarediseases.org

Jerry Williams
Myositis Support and Understanding Association, Inc.
302-339-3241
email us here

Learn more about Myositis Support and Understanding Association, patient-centered nonprofit


Source: EIN Presswire

Azincourt Energy Signs Letter of Intent to Acquire the Macusani-Cuzo Lithium-Uranium Project in Peru

Company to acquire approximately 75,000 acres in one of the largest and highly prospective lithium/uranium districts in the world

Azincourt Energy Corp (OTCBB:AZURF)

VANCOUVER, BC, CANADA, February 20, 2018 /EINPresswire.com/ — Vancouver B.C., February 20, 2018 – AZINCOURT ENERGY CORP. (“Azincourt” or the “Company”; TSX.V: AAZ, OTC: AZURF) is pleased to announce it has signed a non-binding letter of intent (“LOI”) to acquire 99.5% of the outstanding share capital of Guevan Petroleum Company S.A. (“Guevan Petroleum”), a Peruvian private company that currently holds the Macusani-Cuzco lithium-uranium project, located in the Macusani Plateau, Puno, south-eastern Peru.

The Macusani-Cuzco project consists of approximately 30,000 hectares (300-sq kms) located on the Macusani Plateau, one of the largest and highly prospective lithium/uranium districts in the world. The Macusani Plateau features unique, shallow, volcanic-hosted supergene/surficial uranium deposits as well as recently discovered high-grade lithium mineralization.

The Macusani-Cuzco land position is adjacent to the western edge of Plateau Uranium’s (TSX.V: PLU) Macusani Project, which contains the high-grade Falchani discovery with consistent 3,000-3,500 ppm Li over 100m true thickness at depth, and U3O8 grades up to 500 ppm over 50m intercepts from surface*. In addition, surface sampling at Falchani yielded results up to 9,766 ppm U3O8 with 12 samples exceeding 0.1% U3O8, and Li values up to 1,140 ppm Li with 16 samples exceeding 400 ppm Li*.

“We’re pleased to be able to announce this LOI and look forward to executing the due diligence process,” said Alex Klenman, president and CEO. “We’re very aware of the public announcements made by Plateau Uranium, and very impressed with their progress on the plateau and their new Falchani discovery, which features not only high-grade lithium intercepts, but also high-grade uranium mineralization. The Macusani Plateau is both unique and underexplored, and this acquisition allows Azincourt to place a major footprint in what is proving to be an emerging world class district,” continued Mr. Klenman.

The unique volcanic rocks representing the youngest eruptions on the Macusani Plateau host multiple uranium deposits with reported favourable economics (Plateau Uranium – Macusani Project) and are highly prospective for additional discoveries of lithium mineralization at depth as well as uranium-rich surface mineralization. The older volcanic and intrusive rocks deeper in the volcano-plutonic sequence discovered near the present-day edge of the Macusani Plateau also host substantial silver-lead-zinc resources (Bear Creek Mining – Corani Project) and the San Rafael Tin Mine, the largest high-grade tin deposit in the world that has been in production for over 60 years. Other companies including Rio Tinto and Fission Uranium are also active in the area.

In consideration for the acquisition of 99.5% of the outstanding share capital of Guevan Petroleum, the Company has agreed to complete a series of share issuances over a twelve-month period totaling 4,000,000 common shares.

Completion of the transaction with Guevan Petroleum is subject to a number of conditions, including, but not limited to, completion of due diligence, negotiation of definitive documentation in respect of the transaction, and the receipt of any required regulatory approvals, including the approval of the TSX Venture Exchange. The transaction cannot be completed until these conditions are satisfied. Any securities issued in connection with the transaction will be subject to a four-month-and-one-day statutory hold period from the time of issuance.

* Plateau Uranium, January 2018 Investor Presentation

About Azincourt Energy Corp.

Azincourt Energy is a Canadian-based resource company specializing in the strategic acquisition, exploration and development of alternative energy/fuel projects, including lithium, uranium, cobalt and other critical clean energy elements. The Company is currently active at its joint venture lithium exploration projects in the Winnipeg River Pegmatite Field, Manitoba, Canada, and at its East Preston uranium project in the Athabasca Basin, Saskatchewan, Canada.

ON BEHALF OF THE BOARD OF AZINCOURT ENERGY CORP.

“Alex Klenman”
Alex Klenman, President & CEO

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release includes “forward-looking statements”, including forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Azincourt. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward-looking statements. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially.

For further information please contact:

Alex Klenman, President & CEO
Tel: 604-638-8063
info@azincourtenergy.com

Paul Searle, Corporate Communications
Tel: 778-240-7724
psearle@azincourtenergy.com

Azincourt Energy Corp.
430 – 800 West Pender Street
Vancouver, BC
V6C 2V6
www.azincourtenergy.com

Alex Klenman
Azincourt Energy Corp
6046388063
email us here


Source: EIN Presswire

Post-Traumatic Stress Disorder (PTSD) -New Report by Companies Involved in Therapeutics Development, H1 2018

Post-Traumatic Stress Disorder

PUNE, MAHARASHTRA, INDIA, February 20, 2018 /EINPresswire.com/ —

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Post-Traumatic Stress Disorder – Pipeline Review, H1 2018”

Post-Traumatic Stress Disorder

Overview

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811441-post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2018

Top Companies mentioned

Addex Therapeutics Ltd

Bionomics Ltd

Catalyst Pharmaceuticals Inc

Eli Lilly and Co

Synchroneuron Inc

Tonix Pharmaceuticals Holding Corp

Post-Traumatic Stress Disorder Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder  – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 5, 16 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively.

Post-Traumatic Stress Disorder pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Post-Traumatic Stress Disorder – Competitive Analysis

Key players are making innovative developments in Post-Traumatic Stress Disorder industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder.

The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Post-Traumatic Stress Disorder therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2811441-post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2018

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Restless Legs Syndrome – Products under Development by Companies , H1 2018

Restless Legs Syndrome

PUNE, MAHARASHTRA, INDIA, February 20, 2018 /EINPresswire.com/ —

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Restless Legs Syndrome – Pipeline Review, H1 2018”

Restless Legs Syndrome

Overview

Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calf’s or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811440-restless-legs-syndrome-pipeline-review-h1-2018

Top Companies mentioned

Bioprojet SCR

Galenica Ltd

Hisamitsu Pharmaceutical Co Inc

Merz Pharma GmbH & Co KgaA

Mundipharma International Ltd

Omeros Corp

Serina Therapeutics Inc

Restless Legs Syndrome Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome  – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 2 and 3 respectively.

Restless Legs Syndrome pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Restless Legs Syndrome – Competitive Analysis

Key players are making innovative developments in Restless Legs Syndrome industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome.

The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Restless Legs Syndrome therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Restless Legs Syndrome therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2811440-restless-legs-syndrome-pipeline-review-h1-2018

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Post-Operative Pain – Drug Profiles and Pipeline Review, H1 2018

Post-Operative Pain

PUNE, MAHARASHTRA, INDIA, February 20, 2018 /EINPresswire.com/ —

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Post-Operative Pain – Pipeline Review, H1 2018”

Post-Operative Pain

Overview

Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery.

Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811439-post-operative-pain-pipeline-review-h1-2018

Top Companies mentioned

Abide Therapeutics Inc

Cadila Healthcare Ltd

Dompe Farmaceutici SpA

Eupraxia Pharmaceuticals Inc

EyeGate Pharmaceuticals Inc

GW Pharmaceuticals Plc

Heron Therapeutics Inc

Immupharma Plc

iX Biopharma Ltd

Lipocure Ltd

Post-Operative Pain Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain  – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Post-Operative Pain , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 8, 18, 8, 1, 21, 3 and 3 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 1 molecules, respectively.

Post-Operative Pain pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Post-Operative Pain – Competitive Analysis

Key players are making innovative developments in Post-Operative Pain industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain.

The pipeline guide reviews pipeline therapeutics for Post-Operative Pain by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Post-Operative Pain therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Post-Operative Pain therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/sample-request/2811439-post-operative-pain-pipeline-review-h1-2018

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

NORAH TRENT
Wise Guy Reports
+91 841 198 5042
email us here


Source: EIN Presswire

Telerehabilitation Systems Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2025

Latest Report on Telerehabilitation Systems Market Global Analysis & 2025 Forecast Research Study

PUNE, INDIA, February 20, 2018 /EINPresswire.com/ — Global Telerehabilitation Systems Industry

Latest Report on Telerehabilitation Systems Market Global Analysis & 2025 Forecast Research Study

This report studies the global Telerehabilitation Systems market, analyzes and researches the Telerehabilitation Systems development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like 
Philips Healthcare 
Care Innovations LLC 
Bosch Healthcare 
Cisco 
Medvivo Group 
TeleVital 
Cloud Physio 
Jintronix 
C3O telemedicine

Try Sample Report @   https://www.wiseguyreports.com/sample-request/3005258-global-telerehabilitation-systems-market-size-status-and-forecast-2025

Market segment by Regions/Countries, this report covers 
United States 
EU 
Japan 
China 
India 
Southeast Asia

Market segment by Type, the product can be split into 
Textual Based Technology 
Audio Based Technology 
Video Based Technology

Market segment by Application, Telerehabilitation Systems can be split into 
Service Providers 
Payers 
Patients/ Clients

Some points from table of content:

Global Telerehabilitation Systems Market Size, Status and Forecast 2025 
1 Industry Overview of Telerehabilitation Systems 
1.1 Telerehabilitation Systems Market Overview 
1.1.1 Telerehabilitation Systems Product Scope 
1.1.2 Market Status and Outlook 
1.2 Global Telerehabilitation Systems Market Size and Analysis by Regions (2013-2018) 
1.2.1 United States 
1.2.2 EU 
1.2.3 Japan 
1.2.4 China 
1.2.5 India 
1.2.6 Southeast Asia 
1.3 Telerehabilitation Systems Market by Type 
1.3.1 Textual Based Technology 
1.3.2 Audio Based Technology 
1.3.3 Video Based Technology 
1.4 Telerehabilitation Systems Market by End Users/Application 
1.4.1 Service Providers 
1.4.2 Payers 
1.4.3 Patients/ Clients

2 Global Telerehabilitation Systems Competition Analysis by Players 
2.1 Telerehabilitation Systems Market Size (Value) by Players (2013-2018) 
2.2 Competitive Status and Trend 
2.2.1 Market Concentration Rate 
2.2.2 Product/Service Differences 
2.2.3 New Entrants 
2.2.4 The Technology Trends in Future

For Detailed Reading Please visit WiseGuy Reports @     https://www.wiseguyreports.com/reports/3005258-global-telerehabilitation-systems-market-size-status-and-forecast-2025

3 Company (Top Players) Profiles 
3.1 Philips Healthcare 
3.1.1 Company Profile 
3.1.2 Main Business/Business Overview 
3.1.3 Products, Services and Solutions 
3.1.4 Telerehabilitation Systems Revenue (Million USD) (2013-2018) 
3.1.5 Recent Developments 
3.2 Care Innovations LLC 
3.2.1 Company Profile 
3.2.2 Main Business/Business Overview 
3.2.3 Products, Services and Solutions 
3.2.4 Telerehabilitation Systems Revenue (Million USD) (2013-2018) 
3.2.5 Recent Developments 
3.3 Bosch Healthcare 
3.3.1 Company Profile 
3.3.2 Main Business/Business Overview 
3.3.3 Products, Services and Solutions 
3.3.4 Telerehabilitation Systems Revenue (Million USD) (2013-2018) 
3.3.5 Recent Developments 
3.4 Cisco 
3.4.1 Company Profile 
3.4.2 Main Business/Business Overview 
3.4.3 Products, Services and Solutions 
3.4.4 Telerehabilitation Systems Revenue (Million USD) (2013-2018) 
3.4.5 Recent Developments 
3.5 Medvivo Group 
3.5.1 Company Profile 
3.5.2 Main Business/Business Overview 
3.5.3 Products, Services and Solutions 
3.5.4 Telerehabilitation Systems Revenue (Million USD) (2013-2018) 
3.5.5 Recent Developments 
3.6 TeleVital 
3.6.1 Company Profile 
3.6.2 Main Business/Business Overview 
3.6.3 Products, Services and Solutions 
3.6.4 Telerehabilitation Systems Revenue (Million USD) (2013-2018) 
3.6.5 Recent Developments 
3.7 Cloud Physio 
3.7.1 Company Profile 
3.7.2 Main Business/Business Overview 
3.7.3 Products, Services and Solutions 
3.7.4 Telerehabilitation Systems Revenue (Million USD) (2013-2018) 
3.7.5 Recent Developments 
3.8 Jintronix 
3.8.1 Company Profile 
3.8.2 Main Business/Business Overview 
3.8.3 Products, Services and Solutions 
3.8.4 Telerehabilitation Systems Revenue (Million USD) (2013-2018) 
3.8.5 Recent Developments 
3.9 C3O telemedicine 
3.9.1 Company Profile 
3.9.2 Main Business/Business Overview 
3.9.3 Products, Services and Solutions 
3.9.4 Telerehabilitation Systems Revenue (Million USD) (2013-2018) 
3.9.5 Recent Developments

4 Global Telerehabilitation Systems Market Size by Type and Application (2013-2018) 
4.1 Global Telerehabilitation Systems Market Size by Type (2013-2018) 
4.2 Global Telerehabilitation Systems Market Size by Application (2013-2018) 
4.3 Potential Application of Telerehabilitation Systems in Future 
4.4 Top Consumer/End Users of Telerehabilitation Systems

5 United States Telerehabilitation Systems Development Status and Outlook 
5.1 United States Telerehabilitation Systems Market Size (2013-2018) 
5.2 United States Telerehabilitation Systems Market Size and Market Share by Players (2013-2018) 
5.3 United States Telerehabilitation Systems Market Size by Application (2013-2018)

6 EU Telerehabilitation Systems Development Status and Outlook 
6.1 EU Telerehabilitation Systems Market Size (2013-2018) 
6.2 EU Telerehabilitation Systems Market Size and Market Share by Players (2013-2018) 
6.3 EU Telerehabilitation Systems Market Size by Application (2013-2018)

Continued…….

For more information or any query mail at sales@wiseguyreports.com

About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Radiodermatitis H2, Pipeline Review : Key Companies are Making Innovative Developments from last few Years.

Radiodermatitis

PUNE, MAHARASHTRA, INDIA, February 20, 2018 /EINPresswire.com/ —

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Radiodermatitis – Pipeline Review, H2 2017”

Radiodermatitis

Overview

Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients' skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions.

Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2593471-radiodermatitis-pipeline-review-h2-2017

Top Companies mentioned

Daiichi Sankyo Co Ltd

FirstString Research Inc

Foresee Pharmaceuticals LLC

SK Chemicals Co Ltd

viDA Therapeutics Inc

Radiodermatitis Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Radiodermatitis  – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Radiodermatitis , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Radiodermatitis pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Radiodermatitis – Competitive Analysis

Key players are making innovative developments in Radiodermatitis industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis.

The pipeline guide reviews pipeline therapeutics for Radiodermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Radiodermatitis therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Radiodermatitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Radiodermatitis.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2593471-radiodermatitis-pipeline-review-h2-2017

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire